# A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT03478683** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 729 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** budesonide/formoterol
- **DRUG:** albuterol/salbutamol
- **DRUG:** FF/UMEC/VI
- **DRUG:** Placebo to match budesonide/formoterol
- **DRUG:** tiotropium
- **DRUG:** Placebo to match FF/UMEC/VI
- **DRUG:** placebo to match tiotropium
- **DEVICE:** ELLIPTA
- **DEVICE:** MDI
- **DEVICE:** HandiHaler

## Key facts

- **NCT ID:** NCT03478683
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-25
- **Primary completion:** 2019-03-14
- **Final completion:** 2019-03-14
- **Target enrollment:** 729 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03478683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03478683, "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03478683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*